These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 34384530)

  • 21. Moving towards hepatitis B elimination in Gulf Health Council states: From commitment to action.
    Al Awaidy ST; Ezzikouri S
    J Infect Public Health; 2020 Feb; 13(2):221-227. PubMed ID: 31445879
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Status of hepatitis C in Guangzhou from 2005 to 2008].
    Lin CS; Zhao ZX; Zhang XH; Guo XY; Li TG; Chong YT; Gao ZL
    Zhonghua Gan Zang Bing Za Zhi; 2010 Jan; 18(1):63-4. PubMed ID: 20128974
    [No Abstract]   [Full Text] [Related]  

  • 23. WHO targets measles and hepatitis B in Western Pacific.
    Benitez MA
    Lancet; 2003 Sep; 362(9389):1048. PubMed ID: 14526777
    [No Abstract]   [Full Text] [Related]  

  • 24. Viral hepatitis.
    Deinhardt F; Abb J; Assaad F
    WHO Chron; 1983; 37(6):203-7. PubMed ID: 6424338
    [No Abstract]   [Full Text] [Related]  

  • 25. Hepatitis B and C in eastern Europe--the current situation.
    Woynarowski M
    Acta Gastroenterol Belg; 1998; 61(2):202-5. PubMed ID: 9658609
    [No Abstract]   [Full Text] [Related]  

  • 26. Hepatitis C virus elimination: laying the foundation for achieving 2030 targets.
    Dore GJ; Bajis S
    Nat Rev Gastroenterol Hepatol; 2021 Feb; 18(2):91-92. PubMed ID: 33257831
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Meeting of the Strategic Advisory Group of Experts on immunization, October 2016 – conclusions and recommendations.
    Wkly Epidemiol Rec; 2016 Dec; 91(48):561-82. PubMed ID: 27922031
    [No Abstract]   [Full Text] [Related]  

  • 28. [Not Available].
    Nau JY
    Rev Med Suisse; 2017 May; 13(563):1066-1067. PubMed ID: 28636300
    [No Abstract]   [Full Text] [Related]  

  • 29. Preventing the spread of viral hepatitis.
    Frymoyer CL
    Am Fam Physician; 1993 Dec; 48(8):1479-86. PubMed ID: 8249779
    [TBL] [Abstract][Full Text] [Related]  

  • 30. What Stands in the Way of Making Hepatitis B and C Rare Diseases in the United States?
    Buckley GJ; Strom BL
    Ann Intern Med; 2016 Aug; 165(4):284-5. PubMed ID: 27064885
    [No Abstract]   [Full Text] [Related]  

  • 31. The phases of hepatitis C elimination: achieving WHO elimination targets.
    Pedrana A; Munari S; Stoové M; Doyle J; Hellard M
    Lancet Gastroenterol Hepatol; 2021 Jan; 6(1):6-8. PubMed ID: 33308435
    [No Abstract]   [Full Text] [Related]  

  • 32. How far is Mexico from Viral Hepatitis Global Health Sector Strategy 2030 targets.
    García-Sepúlveda CA; Laguna-Meraz S; Panduro A
    Ann Hepatol; 2020; 19(2):123-125. PubMed ID: 32138870
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Surveillance for acute viral hepatitis--United States, 2006.
    Wasley A; Grytdal S; Gallagher K;
    MMWR Surveill Summ; 2008 Mar; 57(2):1-24. PubMed ID: 18354374
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Fighting viral hepatitis B and C in Africa. Focus on Benin].
    Kodjoh N
    Med Sante Trop; 2015; 25(2):141-4. PubMed ID: 26039152
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A model of the economic benefits of global hepatitis C elimination: an investment case.
    Scott N; Kuschel C; Pedrana A; Schroeder S; Howell J; Thompson A; Wilson DP; Hellard M
    Lancet Gastroenterol Hepatol; 2020 Oct; 5(10):940-947. PubMed ID: 32730785
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Countdown to 2030: eliminating hepatitis B disease, China.
    Liu J; Liang W; Jing W; Liu M
    Bull World Health Organ; 2019 Mar; 97(3):230-238. PubMed ID: 30992636
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Viral hepatitis in dialysis units: a changing scenario.
    Maggiore Q; Catalano C
    Contrib Nephrol; 1988; 61():240-53. PubMed ID: 2966034
    [No Abstract]   [Full Text] [Related]  

  • 38. Additional resource needs for viral hepatitis elimination through universal health coverage: projections in 67 low-income and middle-income countries, 2016-30.
    Tordrup D; Hutin Y; Stenberg K; Lauer JA; Hutton DW; Toy M; Scott N; Bulterys M; Ball A; Hirnschall G
    Lancet Glob Health; 2019 Sep; 7(9):e1180-e1188. PubMed ID: 31353061
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Does Pay-For-Performance Program Increase Providers Adherence to Guidelines for Managing Hepatitis B and Hepatitis C Virus Infection in Taiwan?
    Chen HJ; Huang N; Chen LS; Chou YJ; Li CP; Wu CY; Chang YC
    PLoS One; 2016; 11(8):e0161002. PubMed ID: 27517172
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence of antibodies to hepatitis B and C among fire department personnel prior to implementation of a hepatitis B vaccination program.
    Pardoe KL
    J Occup Environ Med; 1996 Feb; 38(2):124-5; author reply 127-8. PubMed ID: 8673515
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.